JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB141432

Nafamostat Mesylate, Protease inhibitor

Be the first to review this product! Submit a review

|

(2 Publications)

MW 539.6 Da, Purity >97%. Broad spectrum, potent protease inhibitor (Ki = 95.3 pM). Inhibits NF-κB activation and complement activation. Selective for human tryptase.
1 Images
Chemical Structure - Nafamostat Mesylate, Protease inhibitor (AB141432)
  • Chemical Structure

Lab

Chemical Structure - Nafamostat Mesylate, Protease inhibitor (AB141432)

2D chemical structure image of ab141432, Nafamostat Mesylate, Protease inhibitor

Key facts

CAS number

82956-11-4

Purity

>97%

Form

Solid

form

Molecular weight

539.6 Da

Molecular formula

C<sub>2</sub><sub>1</sub>H<sub>2</sub><sub>5</sub>N<sub>5</sub>O<sub>8</sub>S<sub>2</sub>

PubChem

5311180

Nature

Synthetic

Solubility

Soluble in DMSO to 100 mM

Soluble in water to 100 mM

Biochemical name

Nafamostat mesylate

Biological description

Broad spectrum, potent protease inhibitor (Ki = 95.3 pM). Inhibits NF-κB activation and complement activation. Selective for human tryptase.

Canonical smiles

CS(=O)(=O)O.CS(=O)(=O)O.C1=CC(=CC=C1C(=O)OC2=CC3=C(C=C2)C=C(C=C3)C(=N)N)N=C(N)N

InChi

InChI=1S/C19H17N5O2.2CH4O3S/c20-17(21)14-2-1-13-10-16(8-5-12(13)9-14)26-18(25)11-3-6-15(7-4-11)24-19(22)23;2*1-5(2,3)4/h1-10H,(H3,20,21)(H4,22,23,24);2*1H3,(H,2,3,4)

InChiKey

SRXKIZXIRHMPFW-UHFFFAOYSA-N

IUPAC Name

(6-carbamimidoylnaphthalen-2-yl) 4-(diaminomethylideneamino)benzoate;methanesulfonic acid

style
left-column

Complementary Products

Biochemicals

AB285399

Glycerol (50%), Sterile Solution

  • 0
  • 0
Primary Antibodies

AB178454

Anti-Endothelin A Receptor/ET-A antibody [UMB-8-37-1]

Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Endothelin A Receptor/ET-A antibody [UMB-8-37-1] (AB178454)

  • 4
  • 1
Primary Antibodies

AB81464

Anti-PHLDA3 antibody [4B6]

Western blot - Anti-PHLDA3 antibody [4B6] (AB81464)

  • 0
  • 0
Biochemicals

AB145610

Sulfo-SANPAH, primary amine-nitrophenylazide crosslinker

Chemical Structure - Sulfo-SANPAH, primary amine-nitrophenylazide crosslinker (AB145610)

  • 0
  • 0
style
left-column
style
left-column

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
Storage information
Store under desiccating conditions|The product can be stored for up to 12 months
style
left-column
style
left-column
style
left-column

Product protocols

style
left-column

Publications (2)

Recent publications for all applications. Explore the full list and refine your search

Frontiers in pharmacology 14:1328950 PubMed38273820

2024

Snakebite drug discovery: high-throughput screening to identify novel snake venom metalloproteinase toxin inhibitors.

Applications

Unspecified application

Species

Unspecified reactive species

Rachel H Clare,Charlotte A Dawson,Adam Westhorpe,Laura-Oana Albulescu,Christopher M Woodley,Nada Mosallam,Daniel J W Chong,Jeroen Kool,Neil G Berry,Paul M O'Neill,Nicholas R Casewell

Nature communications 11:6094 PubMed33323937

2020

A therapeutic combination of two small molecule toxin inhibitors provides broad preclinical efficacy against viper snakebite.

Applications

Unspecified application

Species

Unspecified reactive species

Laura-Oana Albulescu,Chunfang Xie,Stuart Ainsworth,Jaffer Alsolaiss,Edouard Crittenden,Charlotte A Dawson,Rowan Softley,Keirah E Bartlett,Robert A Harrison,Jeroen Kool,Nicholas R Casewell
View all publications
style
left-column
style
left-column
style
right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com